The United Kingdom and the United States have signed a important bilateral deal that will guarantee no levies on UK pharmaceutical shipments entering the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase funding on pharmaceuticals through the NHS. This commitment secures that import taxes on these crucial products will remain at zero for a period of the next three years.
This deal follows recent threats to hike duties on patented drug imports, with figures discussed reaching double the cost.
"This deal with the United Kingdom bolsters the international landscape for new treatments and brings much-needed equity to transatlantic medicine commerce," a release declared.
Economic Impact
Pharmaceuticals constitute one of the the United Kingdom's most significant exports to the United States, which is by far the biggest market for major companies like GSK and AstraZeneca.
Export figures indicate that in the year to the end of the third quarter, the UK shipped pharmaceutical products valued at £11.1bn to the US. This value represented 17.4% of British export trade in that timeframe.
"This agreement protects jobs, increases investment and sets the stage for the UK to establish itself as a global hub for biotech and pharma," a government official commented.
Detailed UK Commitments
The deal involves several specific commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to increase overall NHS spending on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be capped at 15%. Previously, repayments were more than 20%.
Broader Context
The deal takes place against a protracted tension between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
This friction were heightened by assertions that US patients were paying several times more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while substantial expansions have been announced toward US facilities.
The Science Minister stated that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the last ten years.
